Videos

Video of Martha Gulati explaining preventive cardiology advanacements for obese patients. #AHA24 #AHA2024 #CVprev

Martha Gulati highlights 'exciting' progress in preventive cardiology

Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.

Deepak Bhatt, MD, MPH, MBA, director of the Mount Sinai Fuster Heart Hospital, explains the research and therapies in development to treat coronary inflammation. In 2023, the FDA cleared the use colchicine and since there has been an explosion of interest in this area. #TCT #TCT24 #TCT2024 #AHA24

Cardiologist examines the latest breakthroughs in coronary inflammation research

Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.

Immediate Past President of the American College of Cardiology (ACC) Hadley Wilson, MD, FACC, executive vice chair of Atrium Health Sanger Heart and Vascular Institute and a clinical professor of medicine at Wake Forest University School of Medicine, details the top late-breaking studies at AHA 2024. #AHA24 #AHA2024

9 key takeaways from AHA 2024 in Chicago

Hadley Wilson, MD, spoke to Cardiovascular Business at the three-day event to discuss key late-breaking studies and trends. Topics included new drug treatments, AI and much more.

Video interview with J.D. Corl, MD, explaining the use of the new E8 and Javelin Shockwave IVL catheters in PAD.

New balloonless IVL catheter offers an alternative to atherectomy in tight lesions, CTOs

J.D. Corl, MD, shared his experience using two new IVL catheters from Shockwave Medical to treat patients with heavily calcified peripheral arteries. He considers both new devices a significant upgrade. 

Philippe Genereux explains how EARLY TAVR will help raise awareness for undertreatment of TAVR.

New data put a spotlight on troubling TAVR trends

Philippe Genereux, MD, principal investigator of the EARLY TAVR trial, noted that many patients with severe AS still go untreated.

Gilbert Tang, MD, explains new tricuspid TEER TRILUMINATE data that now shows clinical efficacy.

Tricuspid TEER shows clinical efficacy for first time in newest TRILUMINATE data

Gilbert Tang, MD, spoke to Cardiovascular Business about late-breaking data from the TRILUMINATE IDE trial. While early results were promising, these latest findings highlight the TriClip device's true value for the first time.

Video of FDA Commissioner Robert Califf, MD, explaining the need for clinicians to take up fight against health misinformation with grassroots efforts in their communities. #misinformation #FDA #science

FDA commissioner urges clinicians to join fight against medical misinformation

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Sanjit Jolly, MD, says cholchicine failed to help heart attack patients in the CLEAR SYNERGY (OASIS 9) presented as a TCT 2024 late-breaker.

Cardiologist explores why colchicine failed to help heart attack patients

Sanjit S. Jolly, MD, MSc, reviewed his team's late-breaking data on treating heart attack patients with colchicine. "I think inflammation is an important area, but I don't think colchicine is the magic bullet," he said.